Rituximab biosimilar(Shenzhen Main Luck Pharmaceuticals, Inc.)

Primary: To evaluate the similarity of the main pharmacokinetic parameter AUC (0 - t) between recombinant human-mouse chimeric anti-CD20 monoclonal antibody injection (WLB-302) and Rituxima® after a single dose; Secondary: 1. The similarity of AUC0-∞ and Cmax between WLB-302 and Rituxima® after administration; 2. The changes in CD19 and CD20 positive B cell counts between WLB-302 and Rituxima® in patients with non-Hodgkin's lymphoma after administration; 3. The differences in the incidence of adverse events between WLB-302 and Rituxima® in patients with non-Hodgkin's lymphoma after administration, and the changes in ADA, laboratory, vital signs, ECG monitoring, electrocardiogram, and physical examination.